bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD)...
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business Wire
Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT New data from ongoing Phase 3 Northstar-2 (HGB-207) study of LentiGlobin for TDT in patients who do not have ß0/ß0 genotype and Phase 3 Northstar-3 (HGB-212) of patients with ß0/ß0 genotype or an IVS-I-110 mutation New data from ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin for patients with SCD Company to hold conference call and webcast, Friday, June 14 at 8:00 a.m. EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that new data from its investigational gene therapy programs for transfusion-dependent ß-thalassemia (TDT) and sickle cell disease (SCD) will be presented during the 24th European Hematology Association (EHA) Congress in Amsterdam, the Netherlands, June 13-16. blueb
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) had its price target lowered by analysts at Barclays PLC from $4.00 to $2.00. They now have an "overweight" rating on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $0.50 price target on the stock, down previously from $3.00.MarketBeat
BLUE
Earnings
- 11/14/24 - Beat
BLUE
Sec Filings
- 11/14/24 - Form DEFA14A
- 11/14/24 - Form SC
- 11/14/24 - Form S-8
- BLUE's page on the SEC website